GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
-4.97%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$532M
AUM Growth
+$532M
(+6.5%)
Cap. Flow
+$72.8M
Cap. Flow
% of AUM
13.7%
Top 10 Holdings %
Top 10 Hldgs %
50.02%
Holding
51
New
12
Increased
11
Reduced
10
Closed
9
Top Buys
| 1 |
UroGen Pharma
URGN
|
$36.7M |
| 2 |
Alkermes
ALKS
|
$13M |
| 3 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$11.7M |
| 4 |
PTC Therapeutics
PTCT
|
$11.2M |
| 5 |
Replimune Group
REPL
|
$10.9M |
Top Sells
| 1 |
Amylyx Pharmaceuticals
AMLX
|
$20.9M |
| 2 |
Rhythm Pharmaceuticals
RYTM
|
$12.7M |
| 3 |
Viking Therapeutics
VKTX
|
$9.7M |
| 4 |
Mineralys Therapeutics
MLYS
|
$9.31M |
| 5 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
$6.65M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
UroGen Pharma
URGN
$900M
| $36.7M | 6.69% | +2,620,545 | New | +$36.7M |
|
|
ALPN
2
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $35.3M | 6.42% | 3,078,633 -285,055 | -8% | -$3.26M |
|
3
Pliant Therapeutics
PLRX
$101M
| $30.4M | 5.54% | 1,755,184 +205,000 | +13% | +$3.55M |
|
4
Vaxcyte
PCVX
$4B
| $27.1M | 4.93% | 531,211 -58,000 | -10% | -$2.96M |
|
5
Ultragenyx Pharmaceutical
RARE
$2.89B
| $25.9M | 4.72% | 727,426 +50,000 | +7% | +$1.78M |
|
|
6
Alkermes
ALKS
$4.78B
| $24.5M | 4.46% | 875,044 +463,591 | +113% | +$13M |
|
7
RAPT Therapeutics
RAPT
$188M
| $24.2M | 4.41% | 1,458,070 -7,081 | -0.5% | -$118K |
|
8
Zura Bio
ZURA
$133M
| $21.7M | 3.96% | 3,295,000 | – | – |
|
9
Sarepta Therapeutics
SRPT
$1.78B
| $20M | 3.65% | 165,200 +41,600 | +34% | +$5.04M |
|
10
Evolus
EOLS
$494M
| $20M | 3.64% | 2,186,934 -247,114 | -10% | -$2.26M |
|
|
PNT
11
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $19.4M | 3.54% | 2,909,960 -90,040 | -3% | -$601K |
|
12
Cytokinetics
CYTK
$4.23B
| $17.7M | 3.22% | 600,000 | – | – |
|
13
Xenon Pharmaceuticals
XENE
$2.98B
| $17.1M | 3.11% | 500,001 -29,999 | -6% | -$1.02M |
|
14
AnaptysBio
ANAB
$569M
| $16.1M | 2.93% | 894,333 | – | – |
|
15
Immunocore
IMCR
$1.62B
| $15.1M | 2.75% | 290,917 -6,165 | -2% | -$320K |
|
|
JBIO
16
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $14.8M | 2.7% | 1,091,233 +159,075 | +17% | +$2.16M |
|
|
ITCI
17
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $11.7M | 2.13% | +225,000 | New | +$11.7M |
|
18
Aclaris Therapeutics
ACRS
$209M
| $11.6M | 2.11% | 1,691,768 -249,813 | -13% | -$1.71M |
|
|
19
PTC Therapeutics
PTCT
$3.92B
| $11.2M | 2.04% | +500,000 | New | +$11.2M |
|
|
20
Replimune Group
REPL
$422M
| $10.9M | 1.99% | +638,495 | New | +$10.9M |
|
|
OPTN
21
DELISTED
OptiNose
OPTN
| $10.9M | 1.98% | 8,839,939 | – | – |
|
22
Amicus Therapeutics
FOLD
$2.34B
| $10.4M | 1.9% | 857,000 +155,608 | +22% | +$1.89M |
|
23
Arcellx
ACLX
$3.85B
| $10.3M | 1.88% | 287,500 +250,000 | +667% | +$8.97M |
|
|
KRTX
24
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $10.2M | 1.86% | +60,500 | New | +$10.2M |
|
25
Akero Therapeutics
AKRO
$3.74B
| $10M | 1.83% | +198,500 | New | +$10M |
|